Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q13285
UPID:
STF1_HUMAN
Alternative names:
Adrenal 4-binding protein; Fushi tarazu factor homolog 1; Nuclear receptor subfamily 5 group A member 1; Steroid hormone receptor Ad4BP
Alternative UPACC:
Q13285; O15196; Q5T6F5
Background:
Steroidogenic factor 1 (SF-1), also known as Adrenal 4-binding protein and Nuclear receptor subfamily 5 group A member 1, plays a pivotal role in sexual differentiation and the formation of primary steroidogenic tissues. It activates transcription by binding to specific DNA sequences, influencing genes critical for steroid hormone production and reproductive system development.
Therapeutic significance:
SF-1 is linked to various disorders, including 46,XY sex reversal 3, 46,XX sex reversal 4, adrenal insufficiency, premature ovarian failure, and spermatogenic failure. Understanding SF-1's role could unveil new therapeutic strategies for these conditions.